# Compare Sermorelin, Tesamorelin and CJC-1295 — Peptides For Doctors > A side-by-side comparison of three Growth Hormone Axis research peptides — Sermorelin, Tesamorelin, and CJC-1295 — across peptide class, evidence base, administration studied, regulatory status and key cautions. Where Sermorelin, Tesamorelin, and CJC-1295 converge, where they diverge, and how far the evidence behind each actually reaches. ## The short version This page lines up [Sermorelin](/sermorelin), [Tesamorelin](/tesamorelin), and [CJC-1295](/cjc-1295) on the dimensions that matter most when reading GH-axis research: what kind of molecule each one is, where it has been studied, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single most important caution. All three share the same upstream mechanism — they activate the pituitary GHRH receptor to stimulate the body's own GH. They differ in size, half-life, regulatory status, and depth of human evidence. Tesamorelin has the strongest RCT evidence and the only current FDA approval, for a narrow indication. Sermorelin has the most clinical history and former approval. CJC-1295 has the longest half-life and the thinnest human file. None is presented here with a human dose. ## The comparison matrix | Dimension | Sermorelin | Tesamorelin | CJC-1295 | | --- | --- | --- | --- | | Peptide class | GHRH(1-29) N-terminal fragment; amidated 29-aa synthetic peptide | GHRH(1-44) analog with DPP-IV-resistant N-terminal hexenoyl modification; 44-aa | Long-acting GHRH analog; tetrasubstituted hGRF(1-29) with optional albumin-binding DAC; 29-aa | | Most-studied in | Pediatric GH deficiency; older adults (GH/IGF-1 restoration) | HIV-associated lipodystrophy (RCTs); cognition; insulin sensitivity | Pharmacokinetics in healthy adults; serum proteomics | | Evidence base (model) | Pediatric RCTs (approved); older-adult human trials; editorial debate on anti-aging [3][5][7] | Five pooled RCTs (HIV lipodystrophy) [8]; 1 cognition RCT [2]; 1 healthy-men PK study [11] | 2 early PK studies in healthy adults [15][16]; 1 proteomic study [14]; no efficacy trials | | Administration studied | Subcutaneous, intravenous [5][6][7] | Subcutaneous (approved); intravenous (PK study) [11][12] | Subcutaneous [15][16] | | Regulatory status | Former FDA approval (Geref, NDA 020443); withdrawn 2008 commercial; now 503A Category 1 compounded | FDA-approved (NDA 022505, 2010) for HIV lipodystrophy only; all else off-label | Not approved; unfavorable 2024 PCAC compounding review; research chemical | | Key caution | Anti-aging use is not evidence-justified per leading editorial [3]; WADA S2 prohibited | Approval limited to HIV lipodystrophy; fat reaccumulates on discontinuation [12]; WADA S2 | No approved indication; 5-8 day GH/IGF-1 elevation; oncologic-risk theory; WADA S2 [15] | ## Peptide class All three are GHRH analogs, but they differ in length and engineering. Sermorelin is the shortest: 29 amino acids, the minimum fragment of endogenous GHRH that retains full receptor activity. Tesamorelin uses the full 44-amino-acid sequence of endogenous GHRH with an N-terminal hexenoyl group that blocks the DPP-IV protease. CJC-1295 returns to the 1-29 framework but adds four amino-acid substitutions for protease resistance and, in the DAC variant, a reactive C-terminal linker that covalently bonds to circulating albumin. Length and modification depth reflect an evolution from the minimal pharmacophore toward extended pharmacokinetics [1]. ## Most-studied in Each peptide has a home territory in the literature. Sermorelin's clinical record is grounded in pediatric growth hormone deficiency, where it was studied as a diagnostic tool and therapeutic agent from the 1990s, and in small trials on GH/IGF-1 restoration in healthy older men [5][7]. Tesamorelin's domain is HIV-associated lipodystrophy, where it has the most systematic RCT program of the class [8][10][12]. CJC-1295's literature is almost entirely pharmacokinetic — studies measuring how long it keeps GH and IGF-1 elevated in healthy adults, with one proteomic analysis as a side report [14][15][16]. ## Evidence base (model) This is where the three genuinely separate. Tesamorelin has the strongest evidence: five pooled RCTs in HIV lipodystrophy [8], a JAMA-published 6-month trial [10], a 52-week program [12], and a cognition RCT [2]. Sermorelin has historical clinical trial data supporting its former approval [5], plus small human PK and GH-restoration studies [6][7]. CJC-1295 has only two early PK studies in healthy adults — these confirm sustained GH/IGF-1 elevation and preserved pulsatility but represent no efficacy evidence for any indication [15][16]. All three lack long-term safety data in unapproved uses. ## Administration studied Sermorelin has been studied intravenously (PK work; GH provocation) and subcutaneously (clinical treatment) [5][6][7]. Tesamorelin's approved route is subcutaneous; it was also studied intravenously in the healthy-men GH pulsatility PK study [11]. CJC-1295 studies used subcutaneous dosing throughout the published human PK literature [15][16]. Intranasal sermorelin is pharmacologically implausible — the 3-5% intranasal bioavailability documented in the PK study [6] confirms poor mucosal absorption for GHRH peptides of this size. ## Regulatory status Regulatory standing separates the three most sharply. Tesamorelin holds current FDA approval (NDA 022505) specifically for HIV lipodystrophy — all other uses are off-label [9]. Sermorelin held approval as Geref (NDA 020443) for pediatric GH deficiency, withdrawn in 2008 for commercial reasons; it now operates as a 503A Category 1 compounded bulk drug substance, which is the most favorable compounding status available [3]. CJC-1295 has no approval history, was not recommended for the 503A bulk drugs list at the 2024 Pharmacy Compounding Advisory Committee, and is sold solely as a research chemical. All three are prohibited in sport under WADA S2. ## Key caution Each peptide carries a defining caveat. For sermorelin, it is that adult anti-aging use is heavily marketed but the evidence does not justify it — as explicitly stated in a leading Annals of Internal Medicine editorial [3]. For tesamorelin, it is the specificity trap: robust RCT data exist for HIV lipodystrophy, but those data do not transfer directly to general populations, and visceral fat returns within weeks of stopping [12]. For CJC-1295, it is the combination of the thinnest human file and the most sustained GH/IGF-1 elevation — raising the theoretical oncologic and metabolic concerns with no long-term safety data to assess them against [15]. Across all three: the mechanism is well characterized, the pituitary-upstream approach is physiologically sound, and the clinical evidence is very uneven. --- A clinician-facing literature digest — what the research says, stated precisely, with citations and without advice.